186 related articles for article (PubMed ID: 29989312)
1. Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals.
Nagano N; Minegishi A; Ito K; Ando T; Tsutsui T; Ogawa T
Ther Apher Dial; 2018 Dec; 22(6):630-634. PubMed ID: 29989312
[TBL] [Abstract][Full Text] [Related]
2. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
[TBL] [Abstract][Full Text] [Related]
3. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
Yaguchi A; Akahane K; Tsuchioka K; Yonekubo S; Yamamoto S; Tamai Y; Tatemichi S; Takeda H
BMC Nephrol; 2019 Dec; 20(1):465. PubMed ID: 31830936
[TBL] [Abstract][Full Text] [Related]
4. Phosphate binders in chronic kidney disease: a systematic review of recent data.
Floege J
J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Floege J
J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
[TBL] [Abstract][Full Text] [Related]
8. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
9. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
10. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
11. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
Minakuchi H; Yoshida T; Kaburagi N; Fujino T; Endo S; Takemitsu TY; Yamashita N; Itoh H; Oya M
Ren Fail; 2020 Nov; 42(1):799-806. PubMed ID: 32779954
[TBL] [Abstract][Full Text] [Related]
13. Real-World Phosphate Binder Use among Dialysis-Dependent Patients with CKD.
Berner T; Ferro C; Dieguez G; Metz S; Moore J; Szabo E; Kovesdy CP
Nephron; 2023; 147(10):583-590. PubMed ID: 36996774
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
15. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
16. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Schmid H; Lederer SR
Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
[TBL] [Abstract][Full Text] [Related]
17. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
[TBL] [Abstract][Full Text] [Related]
18. The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia.
Daoud K; Badran H; Anwar N; Nguyen T
Nephrol Nurs J; 2023; 50(2):140-144. PubMed ID: 37074939
[TBL] [Abstract][Full Text] [Related]
19. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Autissier V; Damment SJ; Henderson RA
J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
[TBL] [Abstract][Full Text] [Related]
20. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Noto L
J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
